Researchers are exploring better ways to manage people with intermediate or high-risk resected cutaneous melanoma or primary uveal melanoma.
This study is investigating the use of a new blood test to guide when to administer a drug called tebentafusp. Tebentafusp has previously been tested in clinical trials for patients with advanced cutaneous and uveal melanoma. The aim of this study is to determine if tebentafusp can help people with cutaneous or uveal melanoma live longer.